The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients
ID Number 08-1093-00007Principal Investigator(s)
Deborah V. Ascheim
Department(s) or Division(s)
Health Evidence and Policy
The purpose of this prospective, multi-center, double-blind, randomized, sequential dose cohort, sham procedure controlled trial is to define the safety and feasibility, and to explore the efficacy of intra-myocardial injection of mesenchymal precursor cells (RevascorTM) on functional status, myocardial function, cardiomyocyte regeneration, and neovascularization in patients with advanced heart failure, implanted with an FDA-approved LVAD as a bridge to cardiac transplantation.
Recruiting Patients: No